Can a Dog or Cat Supplement Claim to Support Joint Health in Japan? (2026)

In short

Not as a direct therapeutic claim. Japan's Pharmaceuticals and Medical Devices Act (薬機法, the PMD Act) treats a body-structure or body-function claim on pet food or a pet supplement as a drug...

Can a Dog or Cat Supplement Claim to Support Joint Health in Japan? (2026)

Not as a direct therapeutic claim. Japan's Pharmaceuticals and Medical Devices Act (薬機法, the PMD Act) treats a body-structure or body-function claim on pet food or a pet supplement as a drug claim, and the Ministry of Agriculture, Forestry and Fisheries (農林水産省, MAFF) has published the specific body parts and functions that trigger it. A product carrying one of those claims is read as an unapproved 動物用医薬品 (animal drug), regardless of how the formula is substantiated abroad.

Can a Pet Supplement in Japan Carry a Joint-Health or Skin-Health Claim?#

Only if the copy stays on the safe side of a line MAFF has drawn in specific, named terms, and most Western pet supplement marketing sits on the wrong side of it by default. The PMD Act does not ban pet supplements as a category. It bans a narrow set of claim types: wording that implies the product treats, prevents, or supports a named body part or bodily function the way a licensed animal drug would. Joint health, coat health, and digestive health claims are the three categories that come up most often, and all three fall inside the prohibited set MAFF has named.

What Makes a Pet Food Claim "Drug-Like" Under the PMD Act?#

The Act asks whether the product's ingredients, physical form, labelling, or dosing instructions read as drug-like, not whether the company intended a medical claim. A pet food or supplement crosses into that category if any one of those four elements, 成分 (ingredients), 形状 (form), 表示 (labelling), or 用法用量 (directions for use), resembles how a licensed veterinary drug is presented. Labelling is the element most SKUs trip on, because it is the easiest to copy wholesale from a source-market product listing without rethinking it for Japan. A formula that is otherwise unremarkable, fish oil, glucosamine, a probiotic blend, becomes a regulatory problem the moment the label or listing describes what it does to the animal's body in the wrong terms.

Which Body Parts and Functions Does MAFF Treat as Drug-Like?#

MAFF names a specific list, and a claim mentioning any item on it is treated as drug-like regardless of how mild the surrounding language sounds. On the structure side, the named parts are joints (関節), coat or hair (毛), bones (骨), teeth (歯), eyes (目), stomach or abdomen (お腹), and legs and hips (足腰). On the function side, the named items are joint function (関節機能), digestion and absorption (消化・吸収), growth and development (発達・成長), and aging (老化). A listing that says a supplement "supports joint function" or "slows the effects of aging" lands squarely inside this list even if no specific disease or condition is named anywhere in the copy.

This is a narrower and more mechanical test than a general reasonableness standard. It does not turn on whether the claim is true, or whether a comparable claim would be legal in the product's home market. It turns on whether the specific named body part or function appears in the copy at all, in any phrasing that reads as structure or function support rather than plain description of what the product contains.

Is There a Difference Between "Feeding Amount" and "Dosage" Language?#

Yes, and this is one of the more counterintuitive parts of the framework for a brand used to US or EU supplement labelling. Describing how much of the product to give an animal as a feeding amount (給与量) is ordinary pet food language and carries no drug-like risk by itself. The same instruction framed as a dosage (用量), the vocabulary used on a prescription or an approved veterinary drug, pulls the product toward the drug-like reading even where the actual quantity recommended is identical. The distinction is about which register the instruction is written in, not about the number itself, which is why a straight translation of a US feeding chart can fail even when nothing about the recommended amount has changed.

Does the Claims Restriction Reach the Marketplace Listing, or Only the Physical Label?#

It reaches both, and the marketplace listing carries the larger exposure: a physical label is set once at launch, while marketplace copy keeps getting edited. The prohibition on drug-like claims extends to packaging, any insert or leaflet included in the box, and internet advertising, which covers a marketplace listing title, bullet points, and product description in full. A brand that carefully clears its physical label but leaves an Amazon or Rakuten listing running the original US marketing copy, "supports healthy joints," "promotes a shiny coat," has moved the exposure from the bottle to the listing page.

This also means the claims review cannot be a one-time label build that gets filed away. Seasonal promotions, new bullet points, and a template a marketing team reuses across markets all edit the listing without anyone revisiting the claims review, so each change needs the same check the original label went through.

How Does This Compare to a Human Food Label in Japan?#

A human food label and a pet supplement listing are regulated by different logic, which is a common source of confusion for a brand that sells both categories. Human food in Japan carries mandatory label content under the Food Labeling Standards, covered in detail in Does an Imported Food Product Need a Japanese-Language Label to Sell in Japan?, and separately, certain human food products can carry a regulated functional claim through a dedicated approval or notification scheme built for that purpose. Pet food and pet supplements have no equivalent functional-claim pathway. There is no route for a dog or cat product to earn the right to say "supports joint health" through any filing or registration; the claim is either outside the drug-like list entirely, or it is prohibited, with no approval process in between that would make it permitted.

Where Does This Sit Within the PMD Act's Broader Scope?#

The same Act that governs pet food claims also governs medical device registration and pharmaceutical approval in Japan, which is worth understanding if a brand is used to thinking of "medical device law" as a separate, narrower regime. The PMD Act's reach extends well past devices into pharmaceuticals, quasi-drugs, and animal drugs, the category a pet supplement is pulled into once its labelling reads as drug-like. The device side of the Act, covered in Importing Medical Devices to Japan, runs on its own registration and classification process, but both tracks share the same underlying logic: Japan draws the line between a consumer product and a regulated medical article by what the product claims to do as much as by what it contains.

Who Has to Be Named as the Japan Importer Before Any of This Matters?#

The claims question only matters once a product is on sale in Japan, and selling requires a Japan-resident party to carry the business notification and label roles the Pet Food Safety Act (ペットフード安全法) sets up. That Act is administered jointly by MAFF and the Ministry of the Environment (環境省), and it requires a business notification filed before sales start, with the label naming an importer at a Japan address. An import structure that puts a Japan entity in that importer role is a separate decision from the claims question covered here, but the two are connected: the same importer named on the label is also the party exposed if a non-compliant claim triggers a disposal or recall order. The notification mechanics and the choice between an importer of record and a customs clearance appointment are covered in Does a Pet Supplement Need a Japan Pet Food Safety Act Notification?; building that import structure correctly, with the right party named and the right customs attorney appointment in place for clearance, is worth doing before the first shipment moves rather than after a listing is already live. Because this area touches animal-drug law, food and agriculture regulation, and the customs process together, Aplash assesses this individually before any scope or terms are set.

Pulling the claims rule into a short list of what governs a Japan SKU:

(a) A body-structure or body-function claim naming joints, coat, bones, teeth, eyes, stomach, or legs and hips is treated as drug-like under the PMD Act and is prohibited on pet food and pet supplements.

(b) The same applies to function claims naming joint function, digestion and absorption, growth and development, or aging.

(c) Feeding instructions must be framed as a feeding amount (給与量); the same number framed as a dosage (用量) reads as drug-like regardless of the quantity involved.

(d) The prohibition covers the physical package, any leaflet, and marketplace or internet advertising and listing copy as much as the printed label.

(e) There is no functional-claim approval pathway for pet food in Japan comparable to the schemes that exist for some human food products; a claim is either outside the drug-like list or it is not permitted.

(f) The claims question sits alongside, not instead of, the separate requirement to have a Japan-resident business notifier and labelled importer in place under the Pet Food Safety Act.

Frequently Asked Questions#

Can I just translate my US pet supplement label into Japanese and sell it as-is?

No, because a direct translation carries the exact body-structure and body-function vocabulary, joint health, coat health, digestive health, anti-aging, that Japan treats as drug-like. The label and the marketplace listing both need rewriting from the product's actual composition and feeding amount. A translation keeps the words that cause the problem; a rewrite removes them.

Is a vitamin or mineral content statement treated the same as a joint-health claim?

A plain composition statement, glucosamine content, omega-3 content, a vitamin or mineral amount, is treated differently from a claim about what the ingredient does inside the animal's body. The risk appears when that composition language is paired with a statement about effect on a named body part or function; listing an ingredient is different from claiming what that ingredient does to the joint, coat, or digestive system.

Does this claims restriction apply only to the physical bottle, or also to an Amazon or Rakuten listing?

It applies to both. The prohibition on drug-like claims reaches packaging, any insert or leaflet, and internet advertising, which covers marketplace listing titles, bullet points, and product descriptions in full. A compliant physical label paired with an unreviewed marketplace listing still carries the exposure, since the listing copy is reviewed under the same rule as the label itself.

If my supplement already has clinical studies behind its joint-health claim in the US or EU, does that help in Japan?

Not under this framework. The Japanese rule does not test whether a claim is scientifically substantiated; it tests whether the claim names a body part or function on MAFF's list at all. A well-substantiated joint-health claim and an unsubstantiated one are treated identically under the PMD Act's drug-like test, because the test is about the claim's category, not its evidentiary backing.


This article is informational only and does not constitute legal, tax, or regulatory advice. Consult a qualified advisor before acting on the content. Last updated: November 2026.